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costs are not yet clear. Purpose of this project is to explain from the economic point 
of view about the future urologic surgery. Methods: In order to analyse the lapa-
rotomy and robotics techniques, we approached costs and revenues. The formers 
are standardized for each kind of surgery, starting from a common case study led by 
the two hospitals of Modena. The latter are extracted punctually from the internal 
database. Finally we focused on the benefits and complications for the patients 
for the two kinds of techniques. Results: In 2014 the hospitals have provided 91 
robotic surgeries and 25 in open-surgery. Revenues for robotic activities are about 
623.539€ while those for open-surgery are 162.045€ , with an average value for each 
patient respectively of 6.852€ (A) and 6.481€ (B). The average hospitalization for 
robotic activities is about 6 days, versus the 10 days for the open-surgery. From the 
analysis above, the costs of robotics are about 6.000€ (D), while the open-surgery 
2.000€ (E). Average income of robotics (A), standardized to average hospitality (from 
6 to 10 days), gives an amount of 11.420 € (C). Comparing (C) with (B), the 4.000€ of 
marginality equals the gap between (D) and (E). ConClusions: The results show 
no economic differences between the two techniques. However, according to clini-
cal point of view, the strong clinical benefits of robotics are evident. As explicated 
by the literature, the accuracy of robotics technique, combined with a more rapid 
learning curve, guarantee a more rapid recovery of urinary tract functionality. 
Despite the goodness, the simulated analysis embeds limits: there is no warranty 
of transferability.
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HealtH-eCoNomiC ComParisoN of a GNrH-aNtaGoNist (DeGarelix) Vs. 
GNrH-aGoNists CoNsiDeriNG tHe Number-NeeDeD-to-treat to aVoiD 
CarDioVasCular eVeNts
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objeCtives: Recent studies suggest that Androgen-Deprivation-Therapy is associ-
ated with increased risk for patients with hormone-sensitive prostate cancer (PCa) 
and pre-existing cardiovascular (CV) disease. Hereunder, the slightly more expensive 
GnRH-antagonist shows a beneficial risk profile over GnRH-agonists. Therefore the 
objective of the present study was to assess the cost-effectiveness of degarelix com-
pared to GnRH-agonists for PCa-patients with pre-existing CV disease. Methods: 
This analysis is based on a pooled analysis of six Phase III-RCTs comparing GnRH-
agonists with degarelix addressing CV-events in PCa-patients (Albertsen et al.2014). 
For the combined endpoint of CV-events or death a superiority of degarelix was 
determined with a Number-Needed-to-Treat (NNT) of 12. From German sick funds 
perspective, this study estimates and validates the additional degarelix drug costs 
to the cost of one (avoided) CV-event. The CV-event costs were estimated via emer-
gency treatment, inpatient hospital treatment and rehabilitation. The difference of 
these two cost pools divided by 12 (patients) yields the average saving per patient 
and year. To validate the robustness of results, sensitivity analyses were performed 
for choice of comparator, variations in the NNT (number of included studies and 
study length) and real world cost data. Results: Compared to the most commonly 
prescribed GnRH-agonist (Trenantone) additional drug costs for degarelix amount 
to € 3,111 for the treatment of 12 PCa-patients. For the prevention of one CV-event 
average savings of € 8,297 are generated. Hence, average savings of € 432/year/patient 
are generated. While examining only studies with CV-events (NNT= 11) or when 
assuming the same length of all studies (NNT= 13) savings amount to € 495 and 
€ 379, respectively. Switching to compare to the cheapest comparator or taking into 
account CV-event real world cost data (€ 9,392 per event) savings of € 62 and € 523 are 
generated, respectively. ConClusions: Degarelix is cost-effective for PCa-patients 
with increased CV-risk compared to GnRH-agonists, also under consideration of 
various sensitivity analyses.
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objeCtives: Through the earlier detection and removal of cancerous and precan-
cerous adenomas, colorectal cancer (CRC) screening aims to reduce both the risk 
to individuals and burden on healthcare systems. Inadequate bowel preparation 
prior to colonoscopy correlates with a higher rate of missed adenomas, especially 
in the right colon. The differential cost and efficacy of available bowel cleansing 
products mean that healthcare providers are faced with a decision that has both 
economic and public health consequences. A model was therefore constructed to 
investigate the long term benefits of adequate bowel cleansing. Methods: The 
cost-consequence model compares the total cost of colonoscopy, and treatment of 
subsequent CRC, over a 10 year time horizon in a cohort of 10,000 patients aged ≥ 55 
years receiving either 4L of polyethylene glycol (4LPEG), 2L of PEG with ascorbate 
(2LPEG+ASC), or 1L of sodium picosulphate with magnesium citrate (NaPic/MgCit) 
prior to colonoscopy. Rates of successful bowel cleansing, completed colonoscopies, 
and adenoma detection rate (ADR) were obtained from clinical trial data, together 
with published rates of surveillance colonoscopy, associated costs, and healthcare 
resource utilisation in Germany. Results: In the model, poor compliance with 
the higher volume 4LPEG leads to a lower rate of completed colonoscopies, and 
more missed adenomas than with lower volume 2LPEG+ASC. Moreover, the superior 
compliance and higher ADR achieved using 2LPEG+ASC, particularly in the right 
colon, results in more cases of CRC prevented over 10 years than 4LPEG and NaPic/
MgCit (25 and 113 more cases, respectively). Through a decrease in treatment of 
CRC, this equates to an average overall cost saving of € 213 and € 625 per patient, 
respectively, over 10 years. ConClusions: Optimisation of bowel cleansing prior 
to colonoscopy is likely to increase the detection (and removal) of cancerous and 
precancerous adenomas, which may reduce the development of CRC, avoid treat-
ment costs, and reduce mortality.
supportive care (21%), TACE (18%) and TARE (3,5%). The mean duration of treat-
ment with sorafenib (a total of 137 patients) was 6.1 months; the average number 
of TACE and TARE sessions was 2.5 and 1.5 procedures/patient, respectively. The 
total costs of treatment per patient amounted to 12,215€ for sorafenib, 13,419€ 
for TACE and 26,106€ for TARE; variability in treatment patterns among centres 
was observed. ConClusions: The present analysis raises for the first time the 
awareness of the overall costs incurred by the Italian National Healthcare Service 
for different treatments used in intermediate and advanced HCC highlighting the 
need for future research and analysis of the cost- effectiveness of TACE alone or 
combined with sorafenib, in the treatment of HCC.
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objeCtives: Non-small cell lung cancer (NSCLC) accounts for 85-90% of all lung 
cancers. Anaplastic lymphoma kinase (ALK) gene rearrangement mutations are 
found in 4-7% of NSCLC tumours. Crizotinib is indicated for treatment of patients 
with ALK-positive (ALK+) advanced or metastatic NSCLC. However, patients even-
tually progress/develop resistance over time. There is limited evidence on the 
economic burden among Canadian ALK+ NSCLC patients who discontinue crizo-
tinib. Methods: A chart review study was conducted to assess treatment patterns, 
resource utilization and associated costs among patients with locally advanced 
or metastatic ALK+ NSCLC, diagnosed 2010-2015, who were intolerant to or pro-
gressed on crizotinib treatment. Data were collected from medical charts from six 
Canadian oncology centres. Cost estimates were calculated using a ‘bottom-up’ 
approach, where frequency of utilization, retrieved by type and frequency, was 
multiplied by each resource unit cost. Costing was performed with the public 
payer’s perspective, and as ceritinib was approved in March 2015, associated costs 
were excluded. Results: A total of 97 charts were included, with 49 crizotinib-
failures, 9 crizotinib-naive and 39 ongoing crizotinib treatment. Among those who 
failed crizotinib treatment, mean age at diagnosis was 53 years, with 53% female, 
53% Caucasian, and 67% non-smokers. Treatment patterns post crizotinib in any 
line of treatment was ceritinib (43%), targeted therapy (6%), platinum doublets 
(23%), single agent chemotherapy (23%)and no further systemic treatment (41%); 
35% and 33% of patients received concurrent palliative care and/or radiotherapy, 
respectively. Median overall survival in patients who received non-ceritinib treat-
ment was 1.7 months. Total mean cost for completed systemic treatment post-
crizotinib was $16,473/patient, excluding ceritinib costs. Other costs included 
palliative care and radiotherapy. Mean monthly cost for resource use was $4,382/
patient. ConClusions: Treatment patterns post-crizotinib were heterogeneous. 
Estimated economic burden in patients who received active treatment remains 
significant despite their poor prognosis.
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objeCtives: To analyse chemotherapeutic treatment duration, resource use 
and cost per treatment line in metastatic breast cancer (MBC) patients in the 
Netherlands. To analyse lifetime chemotherapy cost and which patient and disease 
characteristics influence it. Methods: A database containing information on 
treatment, disease and patient characteristics of 815 MBC patients was analysed. 
Inclusion criteria were: having a confirmed MBC diagnosis and having received 
at least one chemotherapy administration after MBC diagnosis. On and off treat-
ment duration, number of administrations and mean cost were aggregated for 
each regimen in each treatment line. Chemotherapy costs of each regimen in 
each line were corrected for censoring through the Lin’s method. Corrected costs 
were used to calculate treatment line costs and lifetime cost. A generalised linear 
model was used to assess the influence of patient and disease characteristics on 
lifetime chemotherapy cost. Results: Total chemotherapy line durations and 
off treatment durations were highly variable and decreased across treatment 
lines. Taxane-based chemotherapies (docetaxel and paclitaxel) were the most 
often used regimens in the first two lines of treatment. Afterwards, capecitabine, 
vinorelbine and gemcitabine were more often used. The fifth treatment line was 
the most expensive (mean: € 9,501, range: € 555 - € 31,864), followed by the first line 
(mean: € 4,454, range: € 381 - € 47,872). Mean lifetime costs was € 7,360 (range: € 381 - 
€ 73,512) and was significantly influenced by age and metastatic sites at metastatic 
diagnosis. ConClusions: There is a high variability in chemotherapy treatment 
duration, resource use and cost between and within treatment lines. Lifetime 
chemotherapy cost was influenced by metastatic sites and age at metastatic diag-
nosis. Patient and disease characteristics and treatment line number are therefore 
important when determining the cost of chemotherapy for MBC. Consequently, 
(model-based) economic evaluations should incorporate more detailed cost esti-
mates concerning chemotherapeutic treatment for MBC.
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oPeN surGery aND robotiC teCHNiques
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objeCtives: Among the therapeutic practices for prostate cancer, open-surgery 
is the most frequent technique. Recent studies have shown that robotics allows 
a recovery of the function more rapid than the classic open-surgery, although the 
